Saturday 17 October 2026
Export ELOX’s income statement to Excel — free account
Senesco Technologies Inc.
ELOX Healthcare Biotechnology
Senesco Technologies Inc.’s revenue for fiscal 2024 (year ended December 2024) was $6.4 million. In the quarter to June 2026, EPS grew 87.7% and free cash flow fell 144.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
13.03
0.67
−4.89%
Follow ELOX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | — | |||||
| People | |||||||||||||||
| People | Employees | 5 | 15 | 29 | 29 | 20 | 25 | 15 | — | — | 7 | ||||
| Revenue/emp, $m | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | 0 | — | — | — | — | — | — | — | 6 | — | ||||
| Gross margin, % | 100.00 | — | — | — | — | — | — | — | 100.00 | — | |||||
| EBT | (10) | (21) | (47) | (51) | (35) | (67) | (36) | (17) | (3) | (6) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (49.43) | 0.00 | |||||
| Net income | (10) | (21) | (47) | (51) | (35) | (67) | (36) | (17) | (3) | (6) | |||||
| Depreciation | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.61 | 0.00 | ||||
| Earnings | (1,030.47) | (1,876.02) | (638.06) | (589.66) | (378.44) | (418.04) | (183.17) | (73.37) | (11.00) | (5.34) | |||||
| Cash flow | (921.25) | (1,410.18) | (425.60) | (455.39) | (308.84) | (220.13) | (161.73) | (61.36) | (13.80) | (5.64) | |||||
| Capex | (3.75) | (20.97) | (3.11) | (0.44) | 0.00 | (0.56) | (0.34) | 1.32 | 0.11 | 0.00 | |||||
| Free cash flow | (925.00) | (1,431.15) | (428.71) | (455.83) | (308.84) | (220.69) | (162.07) | (60.04) | (13.69) | (5.64) | |||||
| Book value | 0.00 | 1,890.35 | 582.24 | 418.65 | 112.17 | 140.78 | (54.14) | (96.70) | (71.22) | (10.61) | |||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | 0.00 | — | — | — | — | — | — | — | 0.00 | — | ||||
| P/S | 0.00 | — | — | — | — | — | — | — | 0.00 | — | |||||
| P/B | 0.00 | — | — | — | — | — | — | — | 0.00 | — | |||||
| EV/Sales | 0.00 | — | — | — | — | — | — | — | 0.00 | — | |||||
| EV/FCF | (5.81) | — | — | — | — | — | — | — | (5.81) | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (9) | (16) | (31) | (39) | (28) | (35) | (32) | (14) | (5) | (6) | ||||
| Capex | 0 | 0 | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | (9) | (16) | (32) | (39) | (28) | (35) | (32) | (14) | (5) | (6) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 1 | 21 | 43 | 46 | 16 | 34 | (3) | (21) | (24) | (12) | ||||
| Total debt | — | — | — | 15 | 12 | 12 | 13 | 4 | 7 | 1 | |||||
| Net debt | (1) | (24) | (49) | (41) | (13) | (31) | (7) | 2 | 6 | (4) | |||||
| Shareholders’ equity | 5 | 21 | 43 | 36 | 10 | 22 | (11) | (23) | (24) | (12) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (237.31) | (154.22) | (124.99) | (92.78) | (80.95) | (186.35) | (108.86) | (149.37) | (134.09) | (145.40) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | 0.00 | (212.48) | (146.83) | (128.59) | (148.90) | (409.19) | (615.23) | 102.55 | 13.39 | 33.08 | |||||
Negative figures in brackets.
Fiscal years to Dec 2024 · latest quarter Dec 2015
Charts ten years each
Senesco Technologies Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CNTB Connect Biopharma Holdings Limited Sponsored ADR | $57.1M | — (loss-making) | — (loss-making) | +296.56% (above 0%: growing) | n/m | −23.48% (below 0%: shrinking) | 100.00% | (635.98%) | Compare |
| TENX Tenax Therapeutics, Inc. | $56.5M | — (loss-making) | — | −77.98% (below 0%: shrinking) | n/m | −125.93% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALPS Alps Group Inc. | $56.4M | — (loss-making) | — | — | n/m | −26.48% (below 0%: shrinking) | — | 0.00% | Compare |
| ELOX Senesco Technologies Inc. | $55.3M | — (loss-making) | — | — | n/m | −144.34% (below 0%: shrinking) | 100.00% | 0.00% | |
| GUTS Fractyl Health, Inc. | $55.2M | — (loss-making) | — (loss-making) | −57.14% (below 0%: shrinking) | n/m | +25.34% (above 0%: growing) | 100.00% | 0.00% | Compare |
| GOSS Gossamer Bio, Inc. | $54.3M | — (loss-making) | — (loss-making) | −19.59% (below 0%: shrinking) | n/m | +16.32% (above 0%: growing) | 100.00% | (282.25%) | Compare |
| RNTX Rein Therapeutics Inc. | $54.2M | — (loss-making) | — | — | n/m | −34.62% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RNXT RenovoRx, Inc. | $53.7M | — (loss-making) | — (loss-making) | +115.40% (above 0%: growing) | n/m | −27.63% (below 0%: shrinking) | 84.27% | (368.43%) | Compare |
| BOLD Boundless Bio, Inc. | $53.5M | — (loss-making) | — | — | n/m | −76.90% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $54.8M | — | — | −19.59% | — | −27.05% | 92.14% | 0.00% |
Senesco Technologies Inc. (ELOX) key facts
- Senesco Technologies Inc. (ELOX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Senesco Technologies Inc.’s revenue for fiscal 2024 (year ended December 2024) was $6.4 million.
- As of October 16, 2026, ELOX traded at $13.03, a market capitalization of $55.3 million.
- Return on equity was 33.1% and debt-to-equity 0.00.
Senesco Technologies Inc. (ELOX) Latest News
No news at this impact. Lower the threshold for more.